Taplin M-E, Gleave M, Shore ND, Lopez-Gitlitz A, Kretschmer A, Efstathiou E, et al. Perioperative Apalutamide in High-Risk Localized Prostate Cancer. N Engl J Med. 2026. https://doi.org/10.1056/NEJMoa2603878. NEJMoa2603878.

Article  PubMed  Google Scholar 

Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399:447–60.

Article  CAS  PubMed  Google Scholar 

Franco A, Ditonno F, Manfredi C, Pellegrino AA, Licari LC, Bologna E, et al. Single port robot-assisted radical and simple prostatectomy: a systematic review and meta-analysis. Prostate Cancer Prostat Dis. 2025;28:117–28.

Article  Google Scholar 

Falagario UG, Knipper S, Pellegrino F, Martini A, Akre O, Egevad L, et al. Prostate cancer–specific and all-cause mortality after robot-assisted radical Prostatectomy: 20 years’ report from the European Association of Urology Robotic Urology Section Scientific Working Group. Eur Urol Oncol. 2024;7:705–12.

Article  PubMed  Google Scholar 

Bertini A, Stephens A, Finocchiaro A, Viganò S, Dinesh A, Guivatchian E, et al. Long-term cancer control outcomes after robot-assisted Radical Prostatectomy in pathologically non–organ-confined high-risk prostate cancer: 20-year report from a single tertiary referral center. Eur Urol Focus. 2025;11:904–11.

Article  PubMed  Google Scholar 

NCT04513717. Two Studies for Patients With High-Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial. https://clinicaltrials.gov/study/NCT04513717.

Windisch O, Diana M, Tilki D, Marra G, Martini A, Valerio M. Intraoperative technologies to assess margin status during radical prostatectomy – a narrative review. Prostate Cancer Prostat Dis. 2025;28:81–88.

Article  CAS  Google Scholar 

Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, et al. Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma. N Engl J Med. 2024;390:1359–71.

Article  CAS  PubMed  Google Scholar 

Hahn AW, Koutroumpakis E, Narayan V, Aparicio A. The need for precision medicine in managing cardiovascular risk for men receiving ADT. Prostate Cancer Prostat Dis. 2025;28:245–6.

Article  Google Scholar 

Huggins C, Hodges CV. Studies on Prostatic Cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22:232–40.

CAS  PubMed  Google Scholar 

Moul JW, Boldt-Houle DM, Roach M. Real-world analyses of major adverse cardiovascular events and mortality risk after androgen deprivation therapy initiation in black vs. white prostate cancer patients. Prostate Cancer Prostat Dis. 2025;28:946–52.

Article  CAS  Google Scholar 

Wirth M, Tyrrell C, Wallace M, Delaere KP, Sánchez-Chapado M, Ramon J, et al. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology. 2001;58:146–50.

Article  CAS  PubMed  Google Scholar 

Mari A, Cadenar A, Giudici S, Cianchi G, Albisinni S, Autorino R, et al. A systematic review and meta-analysis to evaluate the diagnostic accuracy of PSMA PET/CT in the initial staging of prostate cancer. Prostate Cancer Prostat Dis. 2025;28:56–69.

Article  CAS  Google Scholar 

Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, et al. Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J Clin Oncol. 2017;35:3097–104.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McKay RR, Montgomery B, Xie W, Zhang Z, Bubley GJ, Lin DW, et al. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. Prostate Cancer Prostat Dis. 2018;21:364–72.

Article  Google Scholar 

Gagnon A, Zhong C, Xie W, Morlock L, Freeman D, Trowbridge R, et al. Testosterone suppression and recovery with abiraterone/prednisone monotherapy after early discontinuation of LHRH-A in hormone sensitive prostate cancer. Prostate Cancer Prostat Dis. 2026;29:449–52.

Article  CAS  Google Scholar 

Ong WL, Romero T, Roy S, Nikitas J, Joseph D, Zapatero A, et al. Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): a pooled analysis of five randomized trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium. Eur Urol. 2025;87:49–57.

Article  CAS  PubMed  Google Scholar 

Rosato R, De Luca S, Zitella A, Munoz F, Baima CG, Barale M, et al. Quality of life in low-risk prostate cancer under active surveillance or following radical treatments: the START cohort study. Prostate Cancer Prostat Dis. 2026;29:189–97.

Article  Google Scholar 

Freedland SJ, Mulhall JP, Gleave M, Giorgi UD, Saad F, Rannikko A, et al. Effects of Enzalutamide on the sexual activity of patients with biochemically recurrent prostate cancer: a post hoc analysis of patient-reported outcomes in the EMBARK Study. Eur Urol. 2025;87:507–511.

Article  CAS  PubMed  Google Scholar